Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.47 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21624752 | 1.00 | MEN1 (0.50) | MEN1KMT2AEPHX2USP30SIGMAR1 | |
| SCHEMBL24244092 | 0.85 | L3MBTL1 (0.50) | KMT2AEPHX2USP30SIGMAR1LMNA | |
| SCHEMBL23750364 | 0.85 | L3MBTL1 (0.50) | KMT2AEPHX2USP30SIGMAR1LMNA | |
| SCHEMBL29689880 | 0.84 | NPC1 (0.62) | MEN1KMT2AEPHX2USP30L3MBTL1 | |
| SCHEMBL21624784 | 0.82 | USP30 (0.49) | MEN1KMT2AUSP30SIGMAR1LMNA | |
| SCHEMBL21624785 | 0.82 | USP30 (0.49) | MEN1KMT2AUSP30SIGMAR1LMNA | |
| SCHEMBL14924027 | 0.82 | L3MBTL1 (0.55) | MEN1KMT2AEPHX2SIGMAR1LMNA | |
| SCHEMBL23387283 | 0.80 | SIGMAR1 (0.64) | MEN1KMT2AEPHX2USP30SIGMAR1 | |
| SCHEMBL23387280 | 0.80 | SIGMAR1 (0.64) | MEN1KMT2AEPHX2USP30SIGMAR1 | |
| SCHEMBL23387204 | 0.79 | ALDH1A1 (0.68) | MEN1KMT2AEPHX2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220226299-A1 | USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING PRURITUS | NIPPON CHEMIPHAR CO., LTD. (JP) | 2022-07-21 | — | — | US | disclosed |
| EP-3950059-A1 | USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING PRURITUS | Nippon Chemiphar Co., Ltd. (JP) | 2022-02-09 | — | — | EP | disclosed |
| EP-3825303-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | Nippon Chemiphar Co., Ltd. (JP) | 2021-05-26 | — | — | EP | disclosed |
| WO-2020017569-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | 日本ケミファ株式会社 | 2020-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220226299-A1 | USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING PRURITUS | TRPV3, CACNA1G, TRPV2 | MEN1 2841/4885KMT2A 2174/4885EPHX2 3565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.